Treatment Sequencing and Clinical Outcomes in BRAF -Positive and BRAF -Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice

ConclusionsInBRAF mutated patients with normal LDH, first-line immunotherapy seems a more effective approach. We have demonstrated that althoughBRAF mutation is a negative prognostic factor in stage IV melanoma, the use of two different systemic treatment modalities allows achievement of comparable survival inBRAF mutated andBRAF wild-type patients.

http://link.springer.com/10.1007/s11523-019-00688-8

Source: Targeted Oncology - November 20, 2019 Category: Cancer & Oncology Source Type: research